AADI Bioscience Seeks New York Court’s Support to Uphold $15 Million Arbitral Award in Cancer Drug Dispute

California-based AADI Bioscience Inc. has approached a federal court in New York with a request to enforce an arbitral award. This award pertains to a dispute over a deal concerning the marketing of a new cancer drug in China, which involved a claim exceeding $15 million from a Hong Kong biopharmaceutical company. AADI is seeking judicial backing to reject this substantial claim, further cementing its position in the high-stakes international pharmaceutical landscape. For further details, the original report is available from Law360.